Heart Failure With Preserved Ejection Fraction Clinical Trials in Pittsburgh, Pennsylvania

4 studies are recruiting for heart failure with preserved ejection fraction in Pittsburgh, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

    This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection frac…

    Stage
    Phase 3
    Ages
    18 to 99
    Site
    University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
    Locations
    657 in total
    Run by
    Amgen
  2. A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)

    This is a Phase 2 placebo-controlled study to evaluate the safety and tolerability of different doses of EDG-15400 in adults with heart failure with preserved ejection fraction (HFpEF).

    Stage
    Phase 2
    Ages
    30 to 84
    Site
    Local Institution - 124, Pittsburgh, Pennsylvania
    Locations
    25 in total
    Run by
    Edgewise Therapeutics, Inc.
  3. Assessment of CCM in HF With Higher Ejection Fraction

    The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.

    Stage
    Not phased
    Ages
    18 and older
    Site
    Allegheny General Hospital, Pittsburgh, Pennsylvania
    Locations
    105 in total
    Run by
    Impulse Dynamics
  4. Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction

    Heart failure with preserved ejection fraction (HFPEF) is common and deadly but without therapy. Inconclusive studies such as TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) suggest spironolactone may be effective in HFPEF, but it is generic and will no…

    Stage
    Phase 3
    Ages
    50 to 99
    Site
    University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
    Locations
    78 in total
    Run by
    Uppsala University

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.